Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Change in Directorate
Appointment of Independent Director17-05-2024
17-05-2024
Zydus Lifesciences Ltd - 532321 - Corporate Action-Board approves Dividend
Final dividend17-05-2024
Zydus Lifesciences Ltd - 532321 - Audited Financial Results For The Quarter And Year Ended On March 31, 2024
Audited financial results for the quarter and year ended on March 31, 202417-05-2024
Zydus Lifesciences Ltd - 532321 - Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended On March 31, 2024
Audited Financial Results for the quarter and year ended on March 31, 202417-05-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus and MSN announces exclusive licensing and supply agreement for Cabozantinib Tablets (generic version of CABOMETYX) for the US marktet.17-05-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of newspaper publication16-05-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from USFDA for Dexamethasone Tablets USP, 1 mg.11-05-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Q4 FY24 post results earning call details10-05-2024
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificates under Reg 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.09-05-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus announces Completion of Enrolment for EPICS IIITM Phase 2b/3 trial evaluating Saroglitazar Mg in treatment of Primary Biliary Cholangitis.09-05-2024